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Abstract
Background: Chronic musculoskeletal pain and depression are very common in primary care patients. Furthermore,
they often appear as comorbid conditions, resulting in additive effect on adverse health outcomes. On the basis of
previous studies, we hypothesise that depression and chronic musculoskeletal pain may benefit from an integrated
management programme at primary care level. We expect positive effects on both physical and psychological
distress of patients.
Methods:
Objective: To determine whether a new programme for an integrated approach to chronic musculoskeletal pain and
depression leads to better outcomes than usual care.
Design: Cluster-randomised controlled trial involving two arms: a) control arm (usual care); and b) intervention arm,
where patients participate in a programme for an integrated approach to the pain-depression dyad.
Settings: Primary care centres in the province of Tarragona, Catalonia, Spain,
Participants: We will recruit 330 patients aged 18–80 with moderate or severe musculoskeletal pain (Brief Pain Inventory,
average pain subscale ≥5) for at least 3 months, and with criteria for major depression (DSM-IV).
Intervention: A multicomponent programme according to the chronic care model. The main components are care
management, optimised antidepressant treatment, and a psychoeducational group action.
Blind measurements: The patients will be monitored through blind telephone interviews held at 0, 3, 6 and 12 months.
Outcomes: Severity of pain and depressive symptoms, pain and depression treatment response rates, and depression
remission rates.
Analysis: The outcomes will be analysed on an intent-to-treat basis and the analysis units will be the individual patients.
This analysis will consider the effect of the study design on any potential lack of independence between observations
made within the same cluster.
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Discussion: This project strengthens and improves treatment approaches for a major comorbidity in primary care. The
design of the intervention takes into account its applicability under typical primary care conditions, so that if the
programme is found to be effective it will be feasible to apply it in a generalised manner.
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Background
Pain and depression are common and relevant condi-
tions in primary care patients [1, 2]. At this level of care
40 % of visits are related to pain, and musculoskeletal
ailments represent the principal chronic pain disorders,
particularly lower back pain and joint pain [3–5]. Major
depression is present in 14 % of all primary care patients
[6] and most of them (up to 85 %) also report pain-
related symptoms [7, 8].
When depression and pain co-occur, both disorders
can have an additive adverse effect on health and its
management: the pain increases the complexity in the
treatment of depression and interferes with recovery,
while depression has a similar effect on the therapeutic
response for the pain [9, 10].
Treatment of individuals with chronic pain and de-
pression is complex. For example, antidepressants, which
are a well-established and effective treatment for depres-
sion, have also been used for musculoskeletal pain disor-
ders but the evidence for their usefulness when applied
in this way is controversial [11]. Care management pro-
grammes for depression have shown promising results
to improve the clinical outcomes in depressed patients
[12], and that interventions are effective and feasible
within our healthcare system [13, 14]. In turn, psychoe-
ducational programmes and programmes supporting
self-management of pain have shown to be somewhat ef-
fective for lower back and joint pains, with additional
benefits on psychological distress [15]. Although of po-
tential interest, these treatment programs are often diffi-
cult to apply in primary care, mostly because their broad
format and complex execution negatively affect their
feasibility in that setting [16, 17].
It therefore seems that a strategy for the joint manage-
ment of chronic pain and depression is a reasonable op-
tion that could be expected to produce a synergistic
effect on clinical outcomes. Based on this premise, in a
study performed in primary care settings Kroenke et al.
developed and tested a programme that integrated opti-
mised antidepressant therapy (actively managed by a
nurse care manager) and a psychoeducational behav-
ioural intervention for pain self-management. There was
evidence for substantial improvement in the depression
symptoms as well as moderate improvements in the pain
and the functional interference they were causing [18].
However, this efficacy and usefulness documented in
United States health settings have not been investigated
in other locations.
Our hypothesis is that both depression and chronic
musculoskeletal pain will benefit from an integrated man-
agement programme for pain-depression comorbidity,
established at the primary care level in our health system.
Positive effects can be expected, with regard to the
physical as well as psychological adjustement of patients.
Methods/design
Aim
The general objective is to study whether a programme
to manage chronic musculoskeletal pain and depression
in primary care results in better outcomes when com-
pared to those achieved through the usual approach.
The specific objectives are to determine, over the course
of a 12-month monitoring period, the effectiveness of
this programme on depression severity, pain severity,
and therapeutic response rates for pain and depression.
Design
A controlled trial will be conducted involving a random
assignment of clusters (patients registered with the same
primary care physician) to two study groups: a) control
group undergoing usual care; and b) treatment group,
where participants will undergo a program for the
integrated management of chronic pain and depression
(Fig. 1).
Setting and study sample
The study will be conducted at the Institut Català de la
Salut (Catalan Health Institute) primary care centres in
the province of Tarragona, Catalonia, Spain.
Patients will be selected from the rosters of the partici-
pating physicians using the following inclusion criteria:
aged 18 to 80 years old, experience moderate or severe
musculoskeletal pain (average pain intensity scale on the
Brief Pain Inventory (BPI) scale ≥ 5 points) for at least
three months despite analgesic treatment, and have diag-
nostic criteria for major depressive episode (DSM-IV).
Aragonès et al. BMC Psychiatry  (2016) 16:69 Page 2 of 9
The following patients will be excluded: those suffering
from any physical, psychological, or language-related limi-
tation, or any concurrent illness that impedes their com-
prehension or participation in the evaluations; patients
with a psychotic disorder, bipolar disorder, or alcohol or
drug dependencies; and patients who are pregnant or lac-
tating. Also considered as ineligible will be patients with
an established diagnosis of fibromyalgia or somatization
disorder; those with a workplace disability claim currently
in progress; and those expecting an intervention for a joint
prosthesis during the next 12 months. If a patient is being
treated with antidepressants, this will not be a criterion
for exclusion as long as the patient shows major depres-
sion criteria at the time of entering into the study.
Random assignment to the study groups
To avoid potential contamination between the interven-
tion and usual care, which could take place if the same
physician were attending patients from the intervention
group and the control group, the patients will be
assigned to the study groups by clusters, with each
cluster comprising patients belonging to the same physi-
cian’s roster.
The clusters from each primary care centre will be
assigned to either the intervention group or control
group by someone not otherwise involved in the study
(Dr. J Basora, Spanish Society of Family and Community
Medicine), following a simple randomised procedure
using the List Randomiser tool at www.random.org. The
physicians will commit to participate in the study prior
to this assignment, and the patients will accept their
recruitment without knowing which study group they
will be assigned to.
The multicomponent program: basic characteristics
The intervention consists of a programme that integrates
and organises several components, designed according to
the basic premises of the chronic care model [19] includ-
ing the following main components:
Optimised management of major depression
Depression will be managed based on the algorithms and
recommendations of the comprehensive clinical guide in
the computerised primary care clinical records. This is a
computerised system used to support clinical decisions
that has been developed based on the most recent clinical
practice guidelines for major depression [20, 21]. It assists
physicians with decisions regarding diagnosis, treatment,
and monitoring of major depression; systems for record-
ing and retrieving information on a patient’s clinical status;
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* eCAP is the acronym for the computerized platform of the primary care clinical records
Fig. 1 Flowchart: sampling, recruitment, randomization and monitoring of patients
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and automated alerts for clinical situations showing poor
control of the illness or risk factors [22].
Care management
The care manager is a psychologist who, based on the al-
gorithms and recommendations from the computerised
guideline, will support and collaborate with the treating
physician in managing the patient, while also providing
support for suitable compliance with the treatment by the
patient and preventing discontinuities in the care. The
care manager will also participate in the monitoring of the
patients. Periodic follow-up will be carried out by tele-
phone. Typically, these phone contacts will occur monthly
during the first two months of the study, then every other
month after that. The content of the telephone contact is
structured and includes: monitoring of symptoms with
the PHQ-9 (Patient Health Questionnaire) scale, the
MINI scale for suicide risk (Mini International Neuro-
psychiatric Interview), and the GAF scale (Global
Assessment of Functioning) to evaluate the impact of
the depression on the patient’s functioning; as well as
evaluating the patient’s compliance with treatment and
identifying any difficulties in this area. These contacts
will also provide the patients with therapeutic advice
and reminders about upcoming visits.
On the basis of the information available through the
computerised system, the care manager will provide the
treating physician with information that will allow him
or her to take the best decisions about health care. The
care manager will also collaborate with the attending
physician to ensure that these decisions (treatment, psy-
choeducation, referrals, new visits, etc.) are taking place
effectively. Supervision and approval of this activity will
be performed on a weekly basis by an expert member of
the research team.
Psychoeducational intervention programme for patients
with chronic pain and depression
This is a group-based psychoeducational programme
with a cognitive-behavioural orientation. It promotes
understanding and self-management of depression and
pain as well as the related difficulties, in order to facili-
tate the acquisition of adaptive strategies for managing
these conditions on a day-to-day basis and provide
incentives for the patient to play an active role in their
illness management [23, 24].
The programme is structured into 9 weekly sessions
of 2 h, led by the care manager. These sessions
include a presentation of the content and dialogue, as
well as interaction between the participants. In order
to promote the active and independent role of the
patient, “homework” is assigned after each session,
which will be reviewed at the beginning of the follow-
ing session. The content of the psychoeducational
sessions covers the following areas: understanding of
pain; managing emotions; basic relaxation techniques;
cognitive restructuring strategies; problem solving;
establishment of life goals; relationships between pain
and physical activity, healthy postures, and sleep;
maintenance of the strategies learned; and preparation
of plans to be applied in the event of temporary
setbacks.
In order to facilitate the sessions, a teaching manual is
made available along with other supporting materials
(slide-based presentations, brochures, and forms).
Usual care (control group)
The physicians will treat the patients assigned to the
usual care group based on their own, unrestricted
criteria, using any resources available that they may
consider appropriate.
Procedure for identifying and recruiting patients
The following procedure will be used to select and
recruit the patients:
1) Using the list of active diagnoses in the computerised
clinical records, a search will be performed for cases
among the rosters of the participating physicians. The
search codes and diagnoses (ICD-10; International
Classification of Diseases, 10th Edition) will be: M15
(polyarthrosis), M16 (coxarthrosis), M17
(gonarthrosis), M19 (other arthrosis), M47
(spondylosis), M50-M51 (disc disorders), M54.2
(cervicalgia), M54.3 to M54.5 (lumbago), M54.6 to
M54.9 (dorsalgia), M25.5 (joint pain), M79.6 (limb
pain), R52.1-R52.2 (chronic pain).
2) Patients identified using these diagnoses will have
their clinical history reviewed manually. Based upon
the information available, patients will be ruled out
if it is established that they do not meet inclusion
criteria.
3) The remaining individuals will be sent a letter with
general information about the study and an
invitation to participate. They will be notified of an
upcoming telephone contact to verify their
eligibility.
4) Two weeks later they will receive a telephone call
during which, with the patient’s consent, screening
tests will be administered in order to identify the
individuals with moderate to severe pain (BPI) for at
least 3 months, as well a positive screening for major
depression (PHQ-9).
5) Patients positively screened for chronic pain and
depression will be selected for an in-person interview
with an independent interviewer to confirm whether
they meet the inclusion/exclusion criteria and to
obtain their informed consent in writing.
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Measurements
Standardised self-report scales will be given in person
(during baseline interview) and on the telephone (follow-
up interviews at 3, 6, and 12 months after recruitment).
Questionnaires will be administered by an independent
qualified interviewer. The interviewer will be blind to
participant’s group.
Measurement variables and tools (Table 1)
Main outcome variables
In accordance with the aims of this study, the major
outcome variables are the measurements of depres-
sion and pain severity as continuous variables, pain
response rate, and depression response and remission
rates.
The severity of depressive symptoms will be measured
by means of the HSCL-20 (Hopkins Symptom Checklist,
20 items) [25]. The items are rated according to the
presence of the symptom in the preceding two weeks on
a Likert scale with five response options, from “not at
all” (0 points) to “extremely” (4 points). The overall
score, which can range between 0 and 4 points, is ob-
tained by calculating the average of the 20 items.
Clinical remission of depression is defined as
complete relief of symptoms and return to full func-
tioning [26] An average point score less than or
equal to 0.5 is an operational indicator of depression
remission [27].
Depression response to treatment is a defined as a 50 %
reduction in the severity of the symptoms with respect
to the baseline HSCL-20 score [26].
The pain intensity and pain interference will be
measured using the 15-item version of the Brief Pain
Inventory [28, 29]. The BPI evaluates two dimensions:
the intensity of the pain and its interference with
everyday activities. The intensity of the pain is mea-
sured using multiple domains (worst pain experi-
enced, minimum pain, average pain, and current
pain), all of which are to be scored using a numerical
rating scale from 0 (no pain) to 10 (worst pain).
Interference with functioning is also measured using
numerical rating scales from 0 (no interference) to 10
(total interference).
A therapeutic response of pain is considered relevant
when a 30 % reduction is observed with respect to the
baseline score [18].
Health-related quality of life will be measured with
the EuroQol-5-D questionnaire [30, 31]. The EQ-5D
has five scales (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) with three levels of
severity (no problems, some problems, and extreme
problems). A global score from 1 (the best state of health)
and 0 (like being dead) can be obtained. The second part
records the subject’s self-assessed health on a Visual
Analogue Scale from 0 (the worst health status) to 100
(the best health status).
Table 1 Study variables
Instrument Assessment area Time (s) of assessment
Brief Pain Inventory (BPI). Average pain scale Pain severity Screening
Patient Health Questionnaire (PHQ-9) Depression symptoms Screening
Sociodemographic data form Age, sex, marital status, educational level, labour status, social class Baseline
SCID (DSM-IV). Major depression module Major depression diagnoses Baseline
Duke Severity of Illness Checklist (DUSOI) Medical comorbidity Baseline
PRIME-MD. Anxiety and dysthymia modules Common psychiatric comorbidity Baseline
Brief Pain Inventory (BPI). Pain severity and interference Baseline, 3, 6 and 12 months
Hopkins Symptom Checklist (HSCL-20) Severity of depressive symptoms, remission and response rates Baseline, 3, 6 and 12 months
EuroQoL-5D Health-related quality of life Baseline, 3, 6 and 12 months
Sheehan Disability Inventory (SDS) Disability due to psychological problems Baseline, 3, 6 and 12 months
Form Days of disability leave from work or interference with usual activities
in the last month
3, 6 and 12 months
Patient Global Impression of Change (PGIC) Patient’s perspective about the efficacy of treatment 3, 6 and 12 months
Use of health resources questionnaire Number of primary care, specialist and emergency visits, and
hospitalisations due to mental health or pain problems
3, 6 and 12 months
Satisfaction with care form Patient’s satisfaction with clinical care received for depression and
pain problems
3, 6 and 12 months
Exploration of the computerised database of
pharmaceutical prescription and invoicing
Pharmacological treatments for pain and depression. Medical
prescription and patient consumption
3, 6 and 12 months
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Secondary variables and effect modifiers
At baseline:
– Sociodemographic information: sex, age, marital
status, education, labour status, and social class
based on occupation [32].
– The severity of physical comorbidity will be
measured using the Duke Severity of Illness
Checklist (DUSOI) [33, 34]. For each diagnosis of a
physical nature, a score is assigned to the symptoms,
complications, prognosis and expected response to
treatment. The overall severity of the patient is
evaluated from 0 to 100.
– To assess the most common psychiatric
comorbidity in depressed patients we will use the
dysthymia and anxiety sections of the Primary
Care Evaluation of Mental Disorders (PRIME-MD).
This interview can generate a range of diagnoses
of mental disorders according to DSM-IV criteria
[35, 36].
– We will establish how long the current depressive
episode has been evolving and any previous history
of depression.
At the baseline and the follow-up interviews, we will
also measure:
– The degree of disability caused by the psychological
disorder will be evaluated using the Sheehan
Disability Inventory (SDI) [37, 38]. This is a
questionnaire with three items evaluating the
disability in the areas of work, social life, and family.
Two additional items evaluate the degree of stress
and the perception of social support. The first four
items are measured using visual analogue scales,
from 0 (no effect) to 10 (extreme effect). Social
support is evaluated in a scale from 0 % (non-
existent social support) to 100 % (ideal social
support).
– The patient’s perspective on the efficacy of
treatment will be assessed using the self-report
Patient Global Impression of Change (PGIC) [39].
This is a 7 point scale depicting a patient’s rating
of overall improvement (from “very much improved”
to “very much worse”).
– Patient satisfaction with the care will be evaluated
using a single item: “How would you rate the quality
of the care you have received (or how they have
dealt with you) for your pain and/or depression
problems?” with five response options in a Likert
scale, from “excellent” to “bad” [40].
– Pharmacological treatments for pain and depression
and use of health resources will be determined by
means of interviewing the patient and exploring
his/her computerised clinical records (i.e., prescription
and pharmacy billing, number and type of primary
care, specialist and emergency visits and




We will consider the response rates to treatment for de-
pression and pain as reference variables. We will assume
that the proportion of patients achieving a therapeutic
response will be 50 % for both outcomes in the control
group [14], and we expect a difference ≥17 % in the
intervention group. Accepting an alpha risk of 0.05 and
a beta risk of 0.2 in a two-tailed test, and with an ex-
pected loss of 15 %, 154 subjects are enough for each
group. We will use the following formula to correct this
figure for the design effect (randomisation by clusters):
Deff = 1 + (m - 1) × ICC, where Deff: design effect; m:
cluster size; and ICC: intraclass correlation coefficient
[41]. Assuming an ICC of 0.01 [14] and m = 8, the Deff
will be 1.07. As such, each study group will require 165
patients (1.07 × 154 = 165), distributed into 21 clusters of
8 patients each.
Analysis strategy
The randomisation will take place at the level of the pri-
mary care physicians (clusters), while the results of the
intervention will be analysed at the individual-patient level
[41]. The principal analyses will be by intention-to-treat,
considering the patients from each group according to the
initial assignment to the study groups, independently of
compliance with the programme by either the individual
patient or the physician.
We will compare the intervention group with the
control group in order to verify that they are comparable
in their baseline characteristics.
The main outcomes (dependent) variables are depres-
sive symptoms (HSCL-20 score), response rate to the de-
pression treatment, remission rate for depression, severity
and interference of the pain (BPI), therapeutic response
rate for the pain, and health-related quality of life at 3, 6,
and 12 months.
In order to evaluate the effects of the intervention on
the dichotomous variables we will use multilevel logistical
regression models with mixed effects, adjusted by cluster,
and employing an estimation of the Odds Ratio (95 % CI)
of the intervention group with respect to the control
group as a measurement of the effect. In order to measure
the effect on the continuous variables we will use linear
regression models with random effects (cluster), estimat-
ing the differences in adjusted averages (95 % CI) for the
intervention group versus control group. For the main
outcome variables we will calculate the intracluster
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correlation coefficient (ICC). Statistical significance will be
established as p < 0.05. We will use STATA-12 and SPSS
v.15 software for these calculations. This analysis strategy
takes into account the design effect (randomisation by
clusters) for any potential lack of independence among
observations within the same primary care centre.
Trial Status and forecast execution dates
Initial recruitment of patients: June 2015; deadline for re-
cruitment of patients: December 2016; deadline for period
of patient monitoring: December 2017; publication of the
results: January-June 2018. The study is ongoing and
currently we are recruiting patients (15 February, 2016;
Ncurrent = 130, out of a foreseen total sample of n = 330).
Ethical aspects
The Study Protocol was approved by the Research Ethics
Committee of the Jordi Gol i Gurina Primary Care
Research Institute (IDIAP), Barcelona, on December
17th, 2014 (ref:P14/142).
The study design involves the need to obtain informed
consent at two levels: a) from the collaborating primary
care physicians; and b) from the participating patients.
The information provided by the research team to the
healthcare professionals will include the voluntary na-
ture of participation and the ability to leave the study
without any negative consequences for the health care of
their patients. The participating professionals will sign a
document stating their commitment to keep patients
informed, verifying the absence of conflicts of interest,
and specifying that their participation in the study will
promote the interests of their patients.
The written information provided by the study inter-
viewer to the patients prior to their consent will include
a general overview of the study’s objectives and activities;
the voluntary nature of his or her participation; the right
to leave the study at any time with a guarantee that they
will continue to receive the treatment their physician
considers most appropriate; and the guarantee that
patients included in the control arm will receive the
treatment that their physician considers to be the most
appropriate, with no restrictions.
If the patient withdraws consent to receive periodic
study assessment, they will be considered to have dropped
out and will not be contacted for periodic assessment in
the future.
All data will be securely held with restricted access
and clinical information will not be used beyond the
objectives of the study.
Discussion
A study performed in the United States has demonstrated
that a programme for the integrated care of depression
and chronic pain can produce improved health-related
results [18]. However, we are unaware of any subsequent
studies that have replicated these results in other environ-
ments, particularly within European healthcare systems.
The objective of this project is to develop a programme
for managing depression and chronic musculoskeletal
pain that is feasible and applicable in the primary care set-
ting within the Spanish healthcare system, and to evaluate
its clinical effectiveness. These objectives fit particularly
well with the strategies currently being promoted by
Spanish and European healthcare authorities [42, 43] to
strengthen and improve the approach to chronic condi-
tions, and specifically for patients with chronic conditions
involving comorbidity and complexity.
This project raises some methodology issues that should
be commented upon. Firstly, randomised assignment by
clusters has been chosen [41] because the intervention to
be evaluated is largely designed to be applied at the pro-
fessional level (e.g., support from the care manager in the
effective use of the computerised clinical guide for depres-
sion), while the results of the intervention are measured in
each patient in the form of health-related outcomes. This
design seeks to avoid any decrease in the effects of the
intervention that could be caused by possible contamin-
ation among the study groups if the randomisation were
to take place on an individual basis, in which case the
same physician would have to provide care to patients
assigned to both the intervention and control groups.
Secondly, the procedure used to identify and recruit
patients eligible for the study is based on a screening.
This prevents any possible selection bias that could exist
if the participating physicians themselves recruited the
patients (e.g., a physician from the intervention group
might be more inclined that a physician from the control
group to recruit patients who are more willing to com-
ply with the treatment). The drawback is that this way of
identifying patients does not correspond with the man-
ner to diagnose chronic pain and depression established
in usual practice, and this could have a certain effect on
the representativeness of the sample. Furthermore, the
fact that individuals are recruited at a point in time
when they are not actively seeking medical care could
cause the sample to include patients who are not
strongly motivated when it comes to the intervention,
particularly towards the psychoeducational programme
which requires a certain level of commitment and
personal effort by the patient.
Thirdly, the intervention incorporates several compo-
nents. It will not be possible to determine which one is
responsible of any observed change/improvement, or even
whether the results are due to the non-specific effects.
The designed intervention relies upon a structured
package of multiple strategies: structured and optimised
management of depression following clinical guides, the
care management, and a psychoeducational intervention
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used to provide patients with the resources and skills to
self-manage their pain and depressive symptomatology.
One of the most innovative aspects is that of defining
and promoting the role of the care manager in the sys-
tematic, structured management of the chronic health
problems experienced by our patients. The innovations
incorporated into this intervention take into account its
feasibility under the typical primary care conditions found
in Spain, so that if the results of the evaluation are
favourable, generalised implementation of the programme
will be feasible.
Ethics approval and consent to participate
Study Protocol approved by the Research Ethics Committee
of the Jordi Gol i Gurina Primary Care Research Institute
(IDIAP), Barcelona, on December 17th, 2014 (ref:P14/142).
The study design involves written informed consent from
the collaborating primary care physicians and from the
participating patients.
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